WallStSmart

Agilent Technologies Inc (A)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 682% more annual revenue ($56.58B vs $7.23B). NVS leads profitability with a 23.9% profit margin vs 19.6%. A appears more attractively valued with a PEG of 1.28. A earns a higher WallStSmart Score of 71/100 (B).

A

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 1.99

NVS

Hold

49

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-73.0%)

Margin of Safety

-73.0%

Fair Value

$74.53

Current Price

$126.49

$51.96 premium

UndervaluedFair: $74.53Overvalued
NVSSignificantly Overvalued (-62.6%)

Margin of Safety

-62.6%

Fair Value

$91.58

Current Price

$148.38

$56.80 premium

UndervaluedFair: $91.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 9.0/10
EPS GrowthGrowth
60.0%10/10

Earnings expanding 60.0% YoY

Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$289.19B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

A3 concerns · Avg: 3.7/10
P/E RatioValuation
26.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NVS4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
4.112/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.28 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : A

The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Key Dynamics to Monitor

A profiles as a mature stock while NVS is a declining play — different risk/reward profiles.

A carries more volatility with a beta of 1.26 — expect wider price swings.

A is growing revenue faster at 10.0% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

A scores higher overall (71/100 vs 49/100), backed by strong 19.6% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?